Multivariate analyses comparing 21FK score with other survival prognostic factors in the CLL cohort and CLL validation cohort
| . | P . | HR . | 95% CI . | |
|---|---|---|---|---|
| Lower . | Upper . | |||
| CLL cohort (n = 104) | ||||
| B2M (≤ 4 mg/L vs > 4 mg/L) | .029 | 3.861 | 1.152 | 12.987 |
| CD19+CD38+ (≤ 34% vs > 34%) | .209 | 2.365 | 0.618 | 9.050 |
| IgVH (nonmutated vs mutated) | .026 | 10.638 | 1.330 | 83.333 |
| ZAP-70 (> 20% vs < 20%) | .120 | 2.642 | 0.778 | 8.976 |
| 21FK score (2/2 vs 1/2 vs 0/2) | .007 | 3.514 | 1.409 | 8.76 |
| CLL validation cohort (n = 80) | ||||
| IgVH (nonmutated vs mutated) | .640 | 7.082 | 0.002 | NA |
| ZAP-70 (≤ 20% vs > 20%) | .690 | 5.311 | 0.001 | NA |
| 21FK score (high vs low) | .013 | 5.217 | 1.408 | 19.327 |
| . | P . | HR . | 95% CI . | |
|---|---|---|---|---|
| Lower . | Upper . | |||
| CLL cohort (n = 104) | ||||
| B2M (≤ 4 mg/L vs > 4 mg/L) | .029 | 3.861 | 1.152 | 12.987 |
| CD19+CD38+ (≤ 34% vs > 34%) | .209 | 2.365 | 0.618 | 9.050 |
| IgVH (nonmutated vs mutated) | .026 | 10.638 | 1.330 | 83.333 |
| ZAP-70 (> 20% vs < 20%) | .120 | 2.642 | 0.778 | 8.976 |
| 21FK score (2/2 vs 1/2 vs 0/2) | .007 | 3.514 | 1.409 | 8.76 |
| CLL validation cohort (n = 80) | ||||
| IgVH (nonmutated vs mutated) | .640 | 7.082 | 0.002 | NA |
| ZAP-70 (≤ 20% vs > 20%) | .690 | 5.311 | 0.001 | NA |
| 21FK score (high vs low) | .013 | 5.217 | 1.408 | 19.327 |
CLL indicates chronic lymphocytic leukemia; HR, hazard ratio; CI, confidence interval; B2M, β-2 microglobulin; IgVH, immunoglobulin heavy-chain variable-region gene; ZAP-70, 70-kDa ζ-associated protein; 21FK, miR-21, FISH, and Karyotype score; and NA, not available.